What is Clostridium Difficile Infections?
Clostridium Difficile Infection (CDI) is a gastrointestinal infection caused by bacterium Clostridium difficile. It commonly affects those individuals who have been exposed to antibiotics therapy, extended hospitalization, and long-term medical care.
How many people are affected by Clostridium Difficile Infections?
- In the US, Clostridium Difficile Infection incidence was 48.53 and 77.49 cases per 100,000 in males and females, respectively in outpatient settings.
- The incidence of Clostridium Difficile Infection at inpatient settings was 63 and 70.77 cases per 100,000 in males and females, respectively.
- Among the Clostridium Difficile Infection patients, female show a higher proportion of incidence as compared to males.
Request for free sample pages @ Clostridium Difficile Infections Market Forecast
How will Clostridium Difficile Infections Market change in upcoming years?
Clostridium Difficile Infection market dynamics is anticipated to change in the coming years owing to the rise in the use of antimicrobial agents, which will result in more Clostridium Difficile Infection incident cases.
The emerging therapies that will boost the Clostridium Difficile Infection market in the coming years includes SER 109, Ridinilazole, RBX2660, CP101, and DAV132.
Companies across the globe are working diligently toward the development of new Clostridium Difficile Infection treatment therapies. The key players are Seres Therapeutics, Summit Therapeutics, Rebiotix Inc., Finch Therapeutics and Da Volterra.
Request for free sample pages @ Clostridium Difficile Infections Market Trends